

Nilesh Kumar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5955600/publications.pdf>

Version: 2024-02-01

55
papers

612
citations

706676

14
h-index

799663

21
g-index

58
all docs

58
docs citations

58
times ranked

441
citing authors

#	ARTICLE	IF	CITATIONS
1	Biosimilar anti-VEGFâ€”Yardsticks to ensure biosimilarity. Eye, 2023, 37, 4-5.	1.1	1
2	Understanding Retinal Vasculitis Associated with Brolucizumab: Complex Pathophysiology or Occamâ€™s Razor?. Ocular Immunology and Inflammation, 2022, 30, 1508-1510.	1.0	16
3	Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study). Eye, 2022, 36, 1106-1107.	1.1	11
4	Faricimab: Two in the Bush Is Proving Better than One in the Hand?. Ocular Immunology and Inflammation, 2022, 30, 1961-1963.	1.0	4
5	Semaglutide and the risk of diabetic retinopathyâ€”current perspective. Eye, 2022, 36, 10-11.	1.1	12
6	Brolucizumabâ€”early experience with early extended interval regime in chronic centre involved diabetic macular oedema. Eye, 2022, 36, 358-360.	1.1	7
7	Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials. Eye, 2022, 36, 679-680.	1.1	5
8	Brolucizumab â€” termination of 4 weekly trials â€” rebalancing the immunogenicity risk. Expert Opinion on Biological Therapy, 2022, 22, 441-443.	1.4	10
9	On label bevacizumab for retina: where it stands. Eye, 2022, 36, 916-917.	1.1	5
10	Ranizurel safety evaluation in real-world -(RaSER) study. American Journal of Ophthalmology Case Reports, 2022, 25, 101358.	0.4	4
11	Retina: a unique subspecialty in the biosimilar landscape. Eye, 2022, , .	1.1	2
12	Reply. Retina, 2022, 42, e20-e22.	1.0	1
13	The port delivery system with ranibizumab: understanding nuances for clinical use in the real world. Expert Opinion on Biological Therapy, 2022, , .	1.4	0
14	Brolucizumab in polypoidal choroidal vasculopathy. Expert Opinion on Biological Therapy, 2022, 22, 809-812.	1.4	0
15	Brolucizumabâ€”early real-world experience: BREW study. Eye, 2021, 35, 1045-1047.	1.1	54
16	Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world. Eye, 2021, 35, 1292-1294.	1.1	23
17	Biosimilars for Retinal Diseases: An Update. American Journal of Ophthalmology, 2021, 224, 36-42.	1.7	33
18	Notion of tolerating subretinal fluid in neovascular AMD: understanding the fine print before the injection pause. British Journal of Ophthalmology, 2021, 105, 149-150.	2.1	6

#	ARTICLE	IF	CITATIONS
19	Brolucizumabâ€™foreseeable workflow in the current scenario. Eye, 2021, 35, 1548-1550.	1.1	15
20	Understanding the Mechanisms of Fluid Development in Age-Related Macular Degeneration. Ophthalmology Retina, 2021, 5, 105-107.	1.2	9
21	Terms non-exudative and non-neovascular: awaiting entry at the doors of AMD reclassification. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 1381-1383.	1.0	7
22	Biosimilar Ranibizumab (SB11) vs Reference Ranibizumabâ€™Diving Deeper for Safety and Efficacy. JAMA Ophthalmology, 2021, 139, 677.	1.4	2
23	Re: Kunimoto etÂal.: Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study (Ophthalmology. 2020;127:1331â€1334). Ophthalmology, 2021, 128, e30.	2.5	0
24	Commentary: Acute central serous chorioretinopathy â€“ Treat early, observe longer. Indian Journal of Ophthalmology, 2021, 69, 2347.	0.5	0
25	Vortex vein anastomosis and pachychoroidâ€™an evolving understanding. Eye, 2021, 35, 1545-1547.	1.1	5
26	The Port Delivery System with ranibizumabâ€™journey of mitigating vitreous hemorrhage. Eye, 2021, , .	1.1	9
27	Fluid-based prognostication in n-AMD: Type 3 macular neovascularisation needs an analysis in isolation. British Journal of Ophthalmology, 2021, 105, 297-298.	2.1	6
28	Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppression. Eye, 2020, 34, 422-423.	1.1	11
29	Brolucizumab: is extended VEGF suppression on the horizon?. Eye, 2020, 34, 424-426.	1.1	7
30	Brolucizimabâ€™leading an era of structural revolution for long-term VEGF suppression. Eye, 2020, 34, 611-613.	1.1	16
31	Abicipar pegol: the non-monoclonal antibody anti-VEGF. Eye, 2020, 34, 797-801.	1.1	15
32	Ophthalmic biosimilars and biologicsâ€™role of endotoxins. Eye, 2020, 34, 614-615.	1.1	11
33	Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective. British Journal of Ophthalmology, 2020, 104, 2-7.	2.1	29
34	Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data. Eye, 2020, 34, 1008-1009.	1.1	16
35	Faricimab: expanding horizon beyond VEGF. Eye, 2020, 34, 802-804.	1.1	54
36	Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect. Eye, 2020, 34, 1006-1007.	1.1	13

#	ARTICLE	IF	CITATIONS
37	Management of Fluid in Neovascular Age-related Macular Degeneration: To Mop it, to Dab it, or to Leave it?. <i>Retina</i> , 2020, 40, 1451-1455.	1.0	11
38	Brolucizumab: the road ahead. <i>British Journal of Ophthalmology</i> , 2020, 104, 1631-1632.	2.1	5
39	Brolucizumab-key learnings from HAWK and HARRIER. <i>Eye</i> , 2020, 34, 1318-1320.	1.1	3
40	Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD). <i>Eye</i> , 2020, 34, 1310-1312.	1.1	5
41	MII RetCam assisted smartphone-based fundus imaging (MSFI)â€”A boon for paediatric retinal imaging. <i>Eye</i> , 2020, 34, 1307-1309.	1.1	9
42	Comment on: â€”Recent advances in anterior chamber angle imagingâ€™. <i>Eye</i> , 2020, 34, 1939-1939.	1.1	0
43	Smartphone based ROP (S-ROP) screeningâ€”opportunities and challenges. <i>Eye</i> , 2020, 34, 1512-1514.	1.1	7
44	Brolucizumab and immunogenicity. <i>Eye</i> , 2020, 34, 1726-1728.	1.1	34
45	Pachydrusen: the epidemiology of pachydrusen and its relevance to progression of pachychoroid disease spectrum. <i>Eye</i> , 2020, 34, 1501-1503.	1.1	7
46	Brolucizumabâ€”another anti-VEGF or beyond. <i>Eye</i> , 2020, 34, 1499-1500.	1.1	7
47	Smartphone-Assisted Glaucoma Screening in Patients With Type 2 Diabetes: a Pilot Study. <i>Medical Hypothesis, Discovery, and Innovation in Ophthalmology</i> , 2020, 9, 61-65.	0.4	5
48	Subfoveal Neurosensory Detachment Flattening and Observe (SNF-Ob): A Novel Approach in Diabetic Macular Edema Management. <i>Ophthalmology Retina</i> , 2019, 3, 1009-1011.	1.2	1
49	Comparison of a Smartphone-Based Photography Method with Indirect Ophthalmoscopic Assessment in Referable Retinopathy of Prematurity. <i>Ophthalmology Retina</i> , 2019, 3, 911-912.	1.2	17
50	Re: Campochiaro etÂal.: The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial (<i>Ophthalmology</i> .) Tj ETQq0 0 0 rgBT /Overlca 10 Tf 50 217 Td (
51	Biologics, biosimilars, and biobetters: different terms or different drugs?. <i>Eye</i> , 2019, 33, 1032-1034.	1.1	10
52	Biotherapeutics and immunogenicity: ophthalmic perspective. <i>Eye</i> , 2019, 33, 1359-1361.	1.1	19
53	Smartphone-based Gonio-Imaging. <i>Journal of Glaucoma</i> , 2019, 28, e149-e150.	0.8	15
54	Ophthalmic biosimilars: Lessons from India. <i>Indian Journal of Ophthalmology</i> , 2019, 67, 1384.	0.5	28

#	ARTICLE	IF	CITATIONS
55	Fear of safety compromise with biosimilar anti-VEGFâ€™ perception or truth. Eye, 0, , .	1.1	2